Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill takes on Hard-to-Treat prostate cancer by targeting a key enzyme and boosting immunity

NCT ID NCT06705686

Recruiting now Disease control Sponsor: TechnoGenesys, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times

Summary

This study tests a new daily pill, (R)-9bMS, for men with metastatic castration-resistant prostate cancer (mCRPC) whose cancer has stopped responding to standard hormone treatments. The drug works by blocking a protein called ACK1 and also helps the immune system fight the tumor. About 40 participants will take the drug twice daily for up to 12 cycles to find the safest dose and see if it can shrink tumors or slow the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA